Scholarlink

<p>Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell malignancy with a poor prognosis. Although the <i>t(11;14)</i> translocation and cyclin D1 expression are defining features, the prognostic significance of CD5 status is debated, especially in the rare CD5-negative subset. Our study aimed to evaluate the relationship between CD5/SOX11 expression and clinicopathological features, and their prognostic impact on patient survival. We retrospectively analyzed data from 205 MCL patients (23 CD5-negative, 182 CD5-positive) diagnosed at …Ege University Faculty of Medicine,………… Hematology Clinic between January 2014 and December 2023. We compared demographic and clinicopathological parameters, including morphology, Ki67 index, and Mantle Cell Lymphoma International Prognostic Index (MIPI) score. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier and Log-Rank tests, while prognostic factors were identified through Cox regression analysis. No statistically significant differences were found between the CD5-negative and CD5-positive groups regarding demographic or clinical features. However, SOX11 expression differed significantly (<i>p</i> = 0.01), with only 56% of CD5-negative patients being SOX11positive compared to 84% of their CD5-positive counterparts. Contrary to some prior largescale studies, no statistically significant difference was demonstrated in OS (<i>p</i> = 0.77) or DFS (<i>p</i> = 0.97) based on CD5 status in our cohort. Notably, morphological subtype showed a borderline significant association with survival (<i>p</i> = 0.05). Our findings suggest that, in our patient cohort, statistical significance could not be demonstrated for CD5 status as an independent prognostic factor. This outcome highlights the need for larger, multi-center studies to definitively clarify the prognostic role of this rare subtype. Our study also underscores the critical importance of evaluating SOX11 expression in CD5-negative cases to ensure diagnostic accuracy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and Pathological Evaluation of CD5/SOX11 Status in Mantle Cell Lymphoma

  • 期刊论文

  • 发表日期：

    2026年5月20日

查看全文
  • Damla Cagla Patir,
  • Ozlem Limoncu,
  • Derya Demir,
  • Nazan Ozsan,
  • Mine Hekimgil,
  • Ajda Günes,
  • Nur Soyer,
  • Fahri Sahin,
  • Filiz Vural,
  • Güray Saydam,
  • Mahmut Töbü

摘要

Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell malignancy with a poor prognosis. Although the t(11;14) translocation and cyclin D1 expression are defining features, the prognostic significance of CD5 status is debated, especially in the rare CD5-negative subset. Our study aimed to evaluate the relationship between CD5/SOX11 expression and clinicopathological features, and their prognostic impact on patient survival. We retrospectively analyzed data from 205 MCL patients (23 CD5-negative, 182 CD5-positive) diagnosed at …Ege University Faculty of Medicine,………… Hematology Clinic between January 2014 and December 2023. We compared demographic and clinicopathological parameters, including morphology, Ki67 index, and Mantle Cell Lymphoma International Prognostic Index (MIPI) score. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier and Log-Rank tests, while prognostic factors were identified through Cox regression analysis. No statistically significant differences were found between the CD5-negative and CD5-positive groups regarding demographic or clinical features. However, SOX11 expression differed significantly (p = 0.01), with only 56% of CD5-negative patients being SOX11positive compared to 84% of their CD5-positive counterparts. Contrary to some prior largescale studies, no statistically significant difference was demonstrated in OS (p = 0.77) or DFS (p = 0.97) based on CD5 status in our cohort. Notably, morphological subtype showed a borderline significant association with survival (p = 0.05). Our findings suggest that, in our patient cohort, statistical significance could not be demonstrated for CD5 status as an independent prognostic factor. This outcome highlights the need for larger, multi-center studies to definitively clarify the prognostic role of this rare subtype. Our study also underscores the critical importance of evaluating SOX11 expression in CD5-negative cases to ensure diagnostic accuracy.